Effects of oral treatments on clinical outcomes in pulmonary arterial hypertension: A systematic review and meta-analysis

American Heart Journal

Volumn 170, Issue 1, 2015, Pages 96-103.e14

  Zhang, Hong Da ^a   Zhang, Rui ^a   Jiang, Xin ^b   Sun, Kai ^b   Wu, Dan Chen ^a   Jing, Zhi Cheng ^a,b  

^a TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

^b FUWAI HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

AMBRISENTAN; ANTIHYPERTENSIVE AGENT; BERAPROST; BOSENTAN; IMATINIB; MACITENTAN; PHOSPHODIESTERASE V INHIBITOR; RIOCIGUAT; SILDENAFIL; SITAXSENTAN; TADALAFIL; TERBOGREL; TREPROSTINIL; VARDENAFIL; BENZAMIDE DERIVATIVE; ENDOTHELIN RECEPTOR ANTAGONIST; PIPERAZINE DERIVATIVE; PROSTAGLANDIN; PROTEIN KINASE INHIBITOR; PYRAZOLE DERIVATIVE; PYRIDINE DERIVATIVE; PYRIMIDINE DERIVATIVE; VASODILATOR AGENT;

ARTICLE; CLINICAL TRIAL (TOPIC); CONSENSUS; EMBASE; FOLLOW UP; HEART INDEX; HEMODYNAMICS; HUMAN; LIFE EXPECTANCY; MEDLINE; META ANALYSIS; MORTALITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PULMONARY HYPERTENSION; QUALITY CONTROL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW; TREATMENT OUTCOME; EXERCISE TEST; HYPERTENSION, PULMONARY; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; ANTIHYPERTENSIVE AGENTS; BENZAMIDES; ENDOTHELIN RECEPTOR ANTAGONISTS; EXERCISE TEST; HUMANS; HYPERTENSION, PULMONARY; PHOSPHODIESTERASE 5 INHIBITORS; PIPERAZINES; PROSTAGLANDINS; PROTEIN KINASE INHIBITORS; PYRAZOLES; PYRIDINES; PYRIMIDINES; TREATMENT OUTCOME; VASODILATOR AGENTS;

EID: 84931568718     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2015.04.003     Document Type: Article

References (43)

1. H.W. Farber, and J. Loscalzo Pulmonary arterial hypertension N Engl J Med 351 2004 1655 1665
2. L.J. Rubin Primary pulmonary hypertension N Engl J Med 336 1997 111 117
3. R.N. Channick, G. Simonneau, and O. Sitbon Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study Lancet 358 2001 1119 1123
4. N. Galiè, M. Humbert, and J.L. Vachiery Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial J Am Coll Cardiol 39 2002 1496 1502
5. L.J. Rubin, D.B. Badesch, and R.J. Barst Bosentan therapy for pulmonary arterial hypertension N Engl J Med 346 2002 896 903
6. D. Langleben, B.W. Christman, and R.J. Barst Effects of the thromboxane synthetase inhibitor and receptor antagonist terbogrel in patients with primary pulmonary hypertension Am Heart J 143 2002 E4
7. R.J. Barst, M. McGoon, and V. McLaughlin Beraprost therapy for pulmonary arterial hypertension J Am Coll Cardiol 41 2003 2119 2125
8. R.J. Barst, D. Langleben, and A. Frost Sitaxsentan therapy for pulmonary arterial hypertension Am J Respir Crit Care Med 169 2004 441 447
9. N. Galiè, H.A. Ghofrani, and A. Torbicki Sildenafil citrate therapy for pulmonary arterial hypertension N Engl J Med 353 2005 2148 2157
10. R.J. Barst, D. Langleben, and D. Badesch Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan J Am Coll Cardiol 47 2006 2049 2056
11. N. Galiè, H. Olschewski, and R.J. Oudiz Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2 Circulation 117 2008 3010 3019
12. N. Galiè, L. Rubin, and M. Hoeper Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial Lancet 371 2008 2093 2100
13. N. Galiè, B.H. Brundage, and H.A. Ghofrani Tadalafil therapy for pulmonary arterial hypertension Circulation 119 2009 2894 2903
14. H.A. Ghofrani, N.W. Morrell, and M.M. Hoeper Imatinib in pulmonary arterial hypertension patients with inadequate response to established therapy Am J Respir Crit Care Med 182 2010 1171 1177
15. Z.C. Jing, Z.X. Yu, and J.Y. Shen Vardenafil in pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled study Am J Respir Crit Care Med 183 2011 1723 1729
16. R.J. Barst, R.J. Oudiz, and A. Beardsworth Tadalafil monotherapy and as add-on to background bosentan in patients with pulmonary arterial hypertension J Heart Lung Transplant 30 2011 632 643
17. V.F. Tapson, F. Torres, and F. Kermeen Oral treprostinil for the treatment of pulmonary arterial hypertension in patients on background endothelin receptor antagonist and/or phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C study): a randomized controlled trial Chest 142 2012 1383 1390
18. J. Sandoval, A. Torbicki, and R. Souza Safety and efficacy of sitaxsentan 50 and 100 mg in patients with pulmonary arterial hypertension Pulm Pharmacol Ther 25 2012 33 39
19. V.F. Tapson, Z.C. Jing, and K.F. Xu Oral treprostinil for the treatment of pulmonary arterial hypertension in patients receiving background endothelin receptor antagonist and phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C2 study): a randomized controlled trial Chest 144 2013 952 958
20. M.M. Hoeper, R.J. Barst, and R.C. Bourge Imatinib mesylate as add-on therapy for pulmonary arterial hypertension: results of the randomized IMPRES study Circulation 127 2013 1128 1138
21. Z.C. Jing, K. Parikh, and T. Pulido Efficacy and safety of oral treprostinil monotherapy for the treatment of pulmonary arterial hypertension: a randomized, controlled trial Circulation 127 2013 624 633
22. T. Pulido, I. Adzerikho, and R.N. Channick Macitentan and morbidity and mortality in pulmonary arterial hypertension N Engl J Med 369 2013 809 818
23. H.A. Ghofrani, N. Galiè, and F. Grimminger Riociguat for the treatment of pulmonary arterial hypertension N Engl J Med 369 2013 330 340
24. S.M. Kawut, E. Bagiella, and D.J. Lederer Randomized clinical trial of aspirin and simvastatin for pulmonary arterial hypertension: ASA-STAT Circulation 123 2011 2985 2993
25. B.K. Sastry, C. Narasimhan, and N.K. Reddy Clinical efficacy of sildenafil in primary pulmonary hypertension: a randomized, placebo-controlled, double-blind, crossover study J Am Coll Cardiol 43 2004 1149 1153
26. I.M. Robbins, S.M. Kawut, and D. Yung A study of aspirin and clopidogrel in idiopathic pulmonary arterial hypertension Eur Respir J 27 2006 578 584
27. A. Bharani, A. Patel, and J. Saraf Efficacy and safety of PDE-5 inhibitor tadalafil in pulmonary arterial hypertension Indian Heart J 59 2007 323 328
28. M.R. Wilkins, O. Ali, and W. Bradlow Simvastatin as a treatment for pulmonary hypertension trial Am J Respir Crit Care Med 181 2010 1106 1113
29. G. Simonneau, A. Torbicki, and M.M. Hoeper Selexipag: an oral, selective prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension Eur Respir J 40 2012 874 880
30. R.J. Barst, L.J. Rubin, and W.A. Long A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension N Engl J Med 334 1996 296 301
31. R.J. Barst, D.D. Ivy, and G. Gaitan A randomized, double-blind, placebo-controlled, dose-ranging study of oral sildenafil citrate in treatment-naive children with pulmonary arterial hypertension Circulation 125 2012 324 334
32. R.L. Benza, D.P. Miller, and R.J. Barst An evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from the REVEAL Registry Chest 142 2012 448 456
33. G.E. D'Alonzo, R.J. Barst, and S.M. Ayres Survival in patients with primary pulmonary hypertension. Results from a national prospective registry Ann Intern Med 115 1991 343 349
34. G. Savarese, S. Paolillo, and P. Costanzo Do changes of 6-minute walk distance predict clinical events in patients with pulmonary arterial hypertension? A meta-analysis of 22 randomized trials J Am Coll Cardiol 60 2012 1192 1201
35. N. Galiè, A. Manes, and L. Negro A meta-analysis of randomized controlled trials in pulmonary arterial hypertension Eur Heart J 30 2009 394 403
36. N. Galiè, P.A. Corris, and A. Frost Updated treatment algorithm of pulmonary arterial hypertension J Am Coll Cardiol 62 25 Suppl. 2013 D60 D72
37. D. Moher, A. Liberati, and J. Tetzlaff Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement Ann Intern Med 151 2009 264 269 [W264]
38. G. Simonneau, M.A. Gatzoulis, and I. Adatia Updated clinical classification of pulmonary hypertension J Am Coll Cardiol 62 25 Suppl. 2013 D34 D41
39. J.P. Higgins, and S. Green Cochrane handbook for systematic reviews of interventions. Version 5.1.0 The Cochrane Collaboration 2011
40. S.J. Brett, J. Simon, and R. Gibbs Impairment of endothelium-dependent pulmonary vasodilation in patients with primary pulmonary hypertension Thorax 51 1996 89 91
41. J.K. Shim, Y.S. Choi, and Y.J. Oh Effect of oral sildenafil citrate on intraoperative hemodynamics in patients with pulmonary hypertension undergoing valvular heart surgery J Thorac Cardiovasc Surg 132 2006 1420 1425
42. S.Y. Kim, J.K. Shim, and Y.H. Shim Sildenafil and beraprost combination therapy in patients with pulmonary hypertension undergoing valvular heart surgery J Heart Valve Dis 19 2010 333 340
43. M. Hatano, A. Yao, and K. Kinugawa Acute effect of sildenafil is maintained in pulmonary arterial hypertension patients chronically treated with bosentan Int Heart J 52 2011 233 239